Stocks · News reference

Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement

Sep 11, 2026, 11:51 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 14, 2026, 11:34 AMBenzinga Newsdesk
Karyopharm Therapeutics Extends Forbearance Period To October 15
As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to
KPTI
SEC EDGAROct 14, 2026, 11:30 AMSEC EDGAR
8-K filing — Karyopharm Therapeutics Inc. (KPTI)
Filed: 2026-10-14 AccNo: 0001193125-26-421025 Size: 136 KB Item 8.01: Other Events
KPTI
BenzingaSep 11, 2026, 5:44 PMBenzinga Newsdesk
Karyopharm Therapeutics shares are trading lower after the company announced a Forbearance Agreement and Limited Waiver to gain time to advance its myelofibrosis program, negotiate with lenders, explore strategic options, or raise equity.
KPTI